These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19830827)

  • 1. Fetal thickened nuchal soft tissues may first appear in the second trimester in Down syndrome.
    Zimmer EZ; Blazer S; Linn S; Bronshtein M
    J Clin Ultrasound; 2010 Feb; 38(2):71-4. PubMed ID: 19830827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of trisomy 21 fetuses with increased nuchal translucency thickness.
    Pandya PP; Snijders RJ; Johnson S; Nicolaides KH
    Ultrasound Obstet Gynecol; 1995 Jun; 5(6):381-3. PubMed ID: 7552798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of detailed first trimester ultrasound examination in abnormal fetal nuchal translucency.
    Bronshtein M; Zimmer EZ; Blazer S
    Prenat Diagn; 2008 Nov; 28(11):1037-41. PubMed ID: 18925580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
    Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
    Thilaganathan B; Slack A; Wathen NC
    Ultrasound Obstet Gynecol; 1997 Oct; 10(4):261-4. PubMed ID: 9383877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Down syndrome screening by ultrasound].
    Rozenberg P
    Gynecol Obstet Fertil; 2005; 33(7-8):526-32. PubMed ID: 16005667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Investigation of ultrasound markers in screening fetal trisomy 21].
    Shi XM; Fang Q; Chen BJ; Xie HN; Xie YJ; Chen JH; Wu JZ
    Zhonghua Fu Chan Ke Za Zhi; 2013 Feb; 48(2):81-5. PubMed ID: 23544486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of nuchal translucency thickening in the fetal chromosome abnormality screening].
    Sun LJ; Wang X; Wu QQ; Ruan Y; Yao L
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):819-23. PubMed ID: 24444557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between nuchal translucency and nuchal skin-fold measurements in Down syndrome and unaffected fetuses.
    Maymon R; Zimerman AL; Weinraub Z; Herman A; Cuckle H
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):501-5. PubMed ID: 18512852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance.
    Bilardo CM; Müller MA; Pajkrt E; Clur SA; van Zalen MM; Bijlsma EK
    Ultrasound Obstet Gynecol; 2007 Jul; 30(1):11-8. PubMed ID: 17559183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability of the first-trimester cardiac scan by ultrasound-trained obstetricians with high-frequency transabdominal probes in fetuses with increased nuchal translucency.
    Bellotti M; Fesslova V; De Gasperi C; Rognoni G; Bee V; Zucca I; Cappellini A; Bulfamante G; Lombardi CM
    Ultrasound Obstet Gynecol; 2010 Sep; 36(3):272-8. PubMed ID: 20499407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal anxiety about first trimester nuchal translucency screening and impact of positive screening results.
    Chueh HY; Cheng PJ; Shaw SW; Lin CT; Hsu JJ; Hsieh TT
    Acta Obstet Gynecol Scand; 2007; 86(12):1437-41. PubMed ID: 17851819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
    Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuchal translucency measurement in first trimester Down syndrome screening.
    Scott A
    Issues Emerg Health Technol; 2007 Jun; (100):1-6. PubMed ID: 17595751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for Down's syndrome by fetal nuchal translucency measurement in a high-risk population.
    Pajkrt E; Mol BW; van Lith JM; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):156-62. PubMed ID: 9793186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-trimester nuchal translucency and cardiac septal defects in fetuses with trisomy 21.
    Hyett JA; Moscoso G; Nicolaides KH
    Am J Obstet Gynecol; 1995 May; 172(5):1411-3. PubMed ID: 7755046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between increased fetal nuchal translucency thickness and chromosomal defects.
    Kagan KO; Avgidou K; Molina FS; Gajewska K; Nicolaides KH
    Obstet Gynecol; 2006 Jan; 107(1):6-10. PubMed ID: 16394033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the importance of second-trimester "soft markers" for trisomy 21 after an 11- to 14-week aneuploidy screening scan?
    Bromley B; Shipp TD; Lyons J; Groszmann Y; Navathe RS; Benacerraf BR
    J Ultrasound Med; 2014 Oct; 33(10):1747-52. PubMed ID: 25253820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fetal karyotyping after 28 weeks of gestation for late ultrasound findings in a low risk population.
    Drummond CL; Gomes DM; Senat MV; Audibert F; Dorion A; Ville Y
    Prenat Diagn; 2003 Dec; 23(13):1068-72. PubMed ID: 14691994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.